MPN patients harbor recurrent truncating mutations in transcription factor NF-E2

Journal of Experimental Medicine

Volumn 210, Issue 5, 2013, Pages 1003-1019

  Jutzi, Jonas S ^a   Bogeska, Ruzhica ^a,b   Nikoloski, Gorica ^c   Schmid, Corina A ^a   Seeger, Thalia S ^a   Stegelmann, Frank ^d   Schwemmers, Sven ^a   Gründer, Albert ^a   Peeken, Jan C ^a   Gothwal, Monika ^a   Wehrle, Julius ^a   Aumann, Konrad ^a   Hamdi, Kamar ^a   Dierks, Christine ^a   Wang, Wei ^a   Döhner, Konstanze ^d   Jansen, Joop H ^c   Pahl, Heike L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR NF E2; DNA; JANUS KINASE 2; MESSENGER RNA; MUTANT PROTEIN; NFE2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; ERYTHROCYTOSIS; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INDEL MUTATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STABILITY; STOP CODON; THROMBOCYTOSIS; WILD TYPE; ANIMAL; BONE MARROW CANCER; CELL CLONE; CELL LINEAGE; CELL STRAIN HEK293; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PROTEIN BINDING; TRANSCRIPTION INITIATION;

ANIMALS; BONE MARROW NEOPLASMS; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CELL PROLIFERATION; CLONE CELLS; DNA; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MICE; MUTANT PROTEINS; MUTATION; MYELOPROLIFERATIVE DISORDERS; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PROTEIN BINDING; PROTEIN STABILITY; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

MLCS; MLOWN;

EID: 84879557768     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20120521     Document Type: Article

References (51)

1. Akashi, K., D. Traver, T. Miyamoto, and I.L. Weissman. 2000. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 404:193-197. http://dx.doi.org/10.1038/35004599
2. Amrolia, P.J., L. Ramamurthy, D. Saluja, N. Tanese, S.M. Jane, and J.M. Cunningham. 1997. The activation domain of the enhancer binding protein p45NF-E2 interacts with TAFII130 and mediates long-range activation of the alpha- and beta-globin gene loci in an erythroid cell line. Proc. Natl. Acad. Sci. USA. 94:10051-10056. http://dx.doi.org/10.1073/pnas.94.19.10051
3. Baxter, E.J., L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, S. Swanton, G.S. Vassiliou, A.J. Bench, E.M. Boyd, N. Curtin, et al; Cancer Genome Project. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054-1061.
4. Ben-David, Y., M.R. Bani, B. Chabot, A. De Koven, and A. Bernstein. 1992. Retroviral insertions downstream of the heterogeneous nuclear ribonucleoprotein A1 gene in erythroleukemia cells: evidence that A1 is not essential for cell growth. Mol. Cell. Biol. 12:4449-4455.
5. Blank, V., M.J. Kim, and N.C. Andrews. 1997. Human MafG is a functional partner for p45 NF-E2 in activating globin gene expression. Blood. 89:3925-3935.
6. Bumm, T.G., C. Elsea, A.S. Corbin, M. Loriaux, D. Sherbenou, L. Wood, J. Deininger, R.T. Silver, B.J. Druker, and M.W. Deininger. 2006. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 66:11156-11165. http://dx.doi.org/10.1158/0008-5472.CAN-06-2210
7. Chaturvedi, C.P., A.M. Hosey, C. Palii, C. Perez-Iratxeta, Y. Nakatani, J.A. Ranish, F.J. Dilworth, and M. Brand. 2009. Dual role for the methyltransferase G9a in the maintenance of beta-globin gene transcription in adult erythroid cells. Proc. Natl. Acad. Sci. USA. 106:18303-18308. http://dx.doi.org/10.1073/pnas.0906769106
8. Chen, X., S. Wen, M.N. Fukuda, N.R. Gavva, D. Hsu, T.O. Akama, T. Yang-Feng, and C.K. Shen. 2001. Human ITCH is a coregulator of the hematopoietic transcription factor NF-E2. Genomics. 73:238-241. http://dx.doi.org/10.1006/geno.2001.6512
9. Christensen, J.L., and I.L. Weissman. 2001. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc. Natl. Acad. Sci. USA. 98:14541-14546. http://dx.doi.org/10.1073/pnas.261562798
10. Consortium, E.P.; ENCODE Project Consortium. 2011. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9:e1001046. http://dx.doi.org/10.1371/journal.pbio.1001046
11. Demers, C., C.P. Chaturvedi, J.A. Ranish, G. Juban, P. Lai, F. Morle, R. Aebersold, F.J. Dilworth, M. Groudine, and M. Brand. 2007. Activator-mediated recruitment of the MLL2 methyltransferase complex to the beta-globin locus. Mol. Cell. 27:573-584. http://dx.doi.org/10.1016/j.molcel.2007.06.022
12. den Dunnen, J.T., and S.E. Antonarakis. 2001. Nomenclature for the description of human sequence variations. Hum. Genet. 109:121-124. http://dx.doi.org/10.1007/s004390100505
13. el-Kassar, N., G. Hetet, J. Brière, and B. Grandchamp. 1997. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 89:128-134.
14. Gavva, N.R., R. Gavva, K. Ermekova, M. Sudol, and C.J. Shen. 1997. Interaction of WW domains with hematopoietic transcription factor p45/NF-E2 and RNA polymerase II. J. Biol. Chem. 272:24105-24108. http://dx.doi.org/10.1074/jbc.272.39.24105
15. Gavva, N.R., S.C. Wen, P. Daftari, M. Moniwa, W.M. Yang, L.P. Yang-Feng, E. Seto, J.R. Davie, and C.K. Shen. 2002. NAPP2, a peroxisomal membrane protein, is also a transcriptional corepressor. Genomics. 79:423-431. http://dx.doi.org/10.1006/geno.2002.6714
16. Goerttler, P.S., C. Kreutz, J. Donauer, D. Faller, T. Maiwald, E. März, B. Rumberger, T. Sparna, A. Schmitt-Gräff, J. Wilpert, et al. 2005. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br. J. Haematol. 129:138-150. http://dx.doi.org/10.1111/j.1365-2141.2005.05416.x
17. Guibal, F.C., M. Alberich-Jorda, H. Hirai, A. Ebralidze, E. Levantini, A. Di Ruscio, P. Zhang, B.A. Santana-Lemos, D. Neuberg, A.J. Wagers, et al. 2009. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood. 114:5415-5425. http://dx.doi.org/10.1182/blood-2008-10-182071
18. Herzinger, T., and S.I. Reed. 1998. Cyclin D3 is rate-limiting for the G1/S phase transition in fibroblasts. J. Biol. Chem. 273:14958-14961. http://dx.doi.org/10.1074/jbc.273.24.14958
19. Hung, H.L., A.Y. Kim, W. Hong, C. Rakowski, and G.A. Blobel. 2001. Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation. J. Biol. Chem. 276:10715-10721. http://dx.doi.org/10.1074/jbc. M007846200
20. Hussein, K., D.L. Van Dyke, and A. Tefferi. 2009. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur. J. Haematol. 82:329-338. http://dx.doi.org/10.1111/j.1600-0609.2009.01224.x
21. Igarashi, K., K. Kataoka, K. Itoh, N. Hayashi, M. Nishizawa, and M. Yamamoto. 1994. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature. 367:568-572. http://dx.doi.org/10.1038/367568a0
22. James, C., V. Ugo, J.P. Le Couédic, J. Staerk, F. Delhommeau, C. Lacout, L. Garçon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144-1148. http://dx.doi.org/10.1038/nature03546
23. Jamieson, C.H., J. Gotlib, J.A. Durocher, M.P. Chao, M.R. Mariappan, M. Lay, C. Jones, J.L. Zehnder, S.L. Lilleberg, and I.L. Weissman. 2006. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl. Acad. Sci. USA. 103:6224-6229. http://dx.doi.org/10.1073/pnas.0601462103
24. Kaufmann, K.B., A. Gründer, T. Hadlich, J. Wehrle, M. Gothwal, R. Bogeska, T.S. Seeger, S. Kayser, K.-B. Pham, J.S. Jutzi, et al. 2012. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J. Exp. Med. 209:35-50. http://dx.doi.org/10.1084/jem.20110540
25. Kiekhaefer, C.M., M.E. Boyer, K.D. Johnson, and E.H. Bresnick. 2004. A WW domain-binding motif within the activation domain of the hematopoietic transcription factor NF-E2 is essential for establishment of a tissue-specific histone modification pattern. J. Biol. Chem. 279:7456-7461. http://dx.doi.org/10.1074/jbc. M309750200
26. Kralovics, R., F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, J.R. Passweg, A. Tichelli, M. Cazzola, and R.C. Skoda. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779-1790. http://dx.doi.org/10.1056/NEJMoa051113
27. Lacout, C., D.F. Pisani, M. Tulliez, F.M. Gachelin, W. Vainchenker, and J.L. Villeval. 2006. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 108:1652-1660. http://dx.doi.org/10.1182/blood-2006-02-002030
28. Lee, T.L., Y.C. Shyu, T.Y. Hsu, and C.K. Shen. 2008. Itch regulates p45/NF-E2 in vivo by Lys63-linked ubiquitination. Biochem. Biophys. Res. Commun. 375:326-330. http://dx.doi.org/10.1016/j.bbrc.2008.07.164
29. Li, Y.J., R.R. Higgins, B.J. Pak, R.A. Shivdasani, P.A. Ney, M. Archer, and Y. Ben-David. 2001. p45(NFE2) is a negative regulator of erythroid proliferation which contributes to the progression of Friend virusinduced erythroleukemias. Mol. Cell. Biol. 21:73-80. http://dx.doi.org/10.1128/MCB.21.1.73-80.2001
30. Mignotte, V., J.F. Eleouet, N. Raich, and P.H. Romeo. 1989. Cis-and trans-acting elements involved in the regulation of the erythroid promoter of the human porphobilinogen deaminase gene. Proc. Natl. Acad. Sci. USA. 86:6548-6552. http://dx.doi.org/10.1073/pnas.86.17.6548
31. Moore, A., M. Merad Boudia, D. Lehalle, W. Massrieh, A. Derjuga, and V. Blank. 2006. Regulation of globin gene transcription by heme in erythroleukemia cells: analysis of putative heme regulatory motifs in the p45 NF-E2 transcription factor. Antioxid. Redox Signal. 8:68-75. http://dx.doi.org/10.1089/ars.2006.8.68
32. Mueller, J.M., and H.L. Pahl. 2000. Assaying NF-kappa B and AP-1 DNAbinding and transcriptional activity. Methods Mol. Biol. 99:205-216.
33. Nikoloski, G., S.M. Langemeijer, R.P. Kuiper, R. Knops, M. Massop, E.R. Tönnissen, A. van der Heijden, T.N. Scheele, P. Vandenberghe, T. de Witte, et al. 2010. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42:665-667. http://dx.doi.org/10.1038/ng.620
34. O'Shea, E.K., R. Rutkowski, and P.S. Kim. 1989. Evidence that the leucine zipper is a coiled coil. Science. 243:538-542. http://dx.doi.org/10.1126/science.2911757
35. Passegué, E., C.H. Jamieson, L.E. Ailles, and I.L. Weissman. 2003. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. USA. 100: 11842-11849. http://dx.doi.org/10.1073/pnas.2034201100
36. Passegué, E., A.J. Wagers, S. Giuriato, W.C. Anderson, and I.L. Weissman. 2005. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202:1599-1611. http://dx.doi.org/10.1084/jem.20050967
37. Raskind, W.H., R. Jacobson, S. Murphy, J.W. Adamson, and P.J. Fialkow. 1985. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J. Clin. Invest. 75:1388-1390. http://dx.doi.org/10.1172/JCI111840
38. Roelz, R., I.H. Pilz, M. Mutschler, and H.L. Pahl. 2010. Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp. Hematol. 38:792-797. http://dx.doi.org/10.1016/j.exphem.2010.05.005
39. Schaub, F.X., R. Looser, S. Li, H. Hao-Shen, T. Lehmann, A. Tichelli, and R.C. Skoda. 2010. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 115:2003-2007. http://dx.doi.org/10.1182/blood-2009-09-245381
40. Schreiber, E., P. Matthias, M.M. Müller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17:6419. http://dx.doi.org/10.1093/nar/17.15.6419
41. Sherr, C.J. 1995. D-type cyclins. Trends Biochem. Sci. 20:187-190. http://dx.doi.org/10.1016/S0968-0004(00)89005-2
42. Sidon, P., P. Heimann, F. Lambert, B. Dessars, V. Robin, and H. El Housni. 2006. Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. Clin. Chem. 52:1436-1438. http://dx.doi.org/10.1373/clinchem.2006.066886
43. Steimle, C., U. Lehmann, S. Temerinac, P.S. Goerttler, H. Kreipe, G. Meinhardt, H. Heimpel, and H.L. Pahl. 2007. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann. Hematol. 86:239-244. http://dx.doi.org/10.1007/s00277-006-0214-1
44. Swerdlow, S., E. Campo, and N. Harris. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IRAC Press Lyon, France. 439 pp.
45. Temerinac, S., S. Klippel, E. Strunck, S. Röder, M. Lübbert, W. Lange, M. Azemar, G. Meinhardt, H.E. Schaefer, and H.L. Pahl. 2000. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 95:2569-2576.
46. Vainchenker, W., F. Delhommeau, S.N. Constantinescu, and O.A. Bernard. 2011. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 118:1723-1735. http://dx.doi.org/10.1182/blood-2011-02-292102
47. Wang, K., S. Swierczek, K. Hickman, H. Hakonarson, and J.T. Prchal. 2011. Convergent mechanisms of somatic mutations in polycythemia vera. Discov. Med. 12:25-32.
48. Wang, W., S. Schwemmers, E.O. Hexner, and H.L. Pahl. 2010. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood. 116: 254-266. http://dx.doi.org/10.1182/blood-2009-11-254664
49. Weber, K., U. Bartsch, C. Stocking, and B. Fehse. 2008. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol. Ther. 16:698-706. http://dx.doi.org/10.1038/mt.2008.6
50. Wernig, G., T. Mercher, R. Okabe, R.L. Levine, B.H. Lee, and D.G. Gilliland. 2006. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 107:4274-4281. http://dx.doi.org/10.1182/blood-2005-12-4824
51. Zaleskas, V.M., D.S. Krause, K. Lazarides, N. Patel, Y. Hu, S. Li, and R.A. Van Etten. 2006. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 1:e18. http://dx.doi.org/10.1371/journal.pone.0000018